Agree it's too early to talk buyout - CRMD has a great plan to penetrate hospitals with very favorable pricing in the near term.  Then expanding to dialysis centers with TADAPA, then expanded usage into oncology and TPN.  Both hospitals and dialysis centers are concentrated distribution channels making  it easy to sell-in without huge sales force.  And not only is Defencath easy to administer it will add revenue/profit to for customers making sell-in that much easier. I will be very interested to see initial revenue forecasts with more detailed pricing and penetration estimates, but this should be at least $2B+ in revenue before oncology.

 

Current market cap is only $160M, so even $1B in revenue with 5x multiple would make this  $100+ pps.  Hope CRMD will let the stock run into the teens before accessing ATM.